Analysis of the Efficacy and the Long-term Metabolic and Nutritional Status of Sleeve Gastrectomy with Transit Bipartition Compared to Roux-en-Y Gastric Bypass in Obese Rats.
Bariatric surgery
Rodent model
Roux-en-Y gastric bypass
Sleeve gastrectomy with transit bipartition
Translational model
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
18
06
2022
accepted:
19
01
2023
revised:
12
01
2023
medline:
10
4
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
Sleeve gastrectomy with transit bipartition (SG-TB) could be an attractive alternative to Roux-en-Y gastric bypass (RYGB) on weight loss and improvement of comorbidities in patients with obesity. However, there is little long-term data. Translational research on a rat model could allow long-term projection to assess efficacy and safety of SG-TB. The aim of this research was to evaluate the long-term efficacy and safety of SG-TB compared to RYGB and SHAM in rat model. Ninety-four male obese Wistar rats were distributed into 3 groups: SG-TB (n = 34), RYGB (n = 32), and SHAM (control group, n = 28). The percentage of total weight loss (%TWL), coprocalorimetry, glucose and insulin tolerance test, insulin, GLP-1, PYY, and GIP before and after surgery were assessed. The animals were followed over 6 months (equivalent to 16 years in humans). At 6 months, %TWL was significantly greater(p = 0.025) in the SG-TB group compared to the RYGB group. There was no difference between the groups (p = 0.86) in malabsorption 15 and 120 days postoperatively. Glucose tolerance was significantly improved (p = 0.03) in the SG-TB and RYGB groups compared to the preoperative state. Insulin secretion, at 3 months, was significantly more important in the SG-TB group (p = 0.0003), compared to the RYGB and SHAM groups. GLP-1 secretion was significantly increased in the SG-TB and RYGB groups compared to the preoperative state (p = 0.001) but similar between SG-TB and RYGB animals (p = 0.72). In a rat model, at long term compared to RYGB, SG-TB provides greater and better-maintained weight loss and an increased insulin secretion without impairing nutritional status.
Identifiants
pubmed: 36729363
doi: 10.1007/s11695-023-06477-7
pii: 10.1007/s11695-023-06477-7
doi:
Substances chimiques
Insulin
0
Glucagon-Like Peptide 1
89750-14-1
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1121-1132Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.
doi: 10.1056/NEJMoa066254
pubmed: 17715408
Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000;232:515–29.
doi: 10.1097/00000658-200010000-00007
pubmed: 10998650
pmcid: 1421184
Sjöström L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.
doi: 10.1056/NEJMoa035622
pubmed: 15616203
Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10:653–62.
doi: 10.1016/S1470-2045(09)70159-7
pubmed: 19556163
Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311:2297.
doi: 10.1001/jama.2014.5988
pubmed: 24915261
Clapp B, Ponce J, DeMaria E, Ghanem O, Hutter M, Kothari S, et al. American Society for Metabolic and Bariatric Surgery 2020 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 2022;18:1134–40.
doi: 10.1016/j.soard.2022.06.284
pubmed: 35970741
Prachand VN, Davee RT, Alverdy JC. Duodenal switch provides superior weight loss in the super-obese (BMI > or =50 kg/m2) compared with gastric bypass. Ann Surg. 2006;244:611–9.
pubmed: 16998370
pmcid: 1856567
Santoro S, Castro LC, Velhote MCP, Malzoni CE, Klajner S, Castro LP, et al. Sleeve gastrectomy with transit bipartition: a potent intervention for metabolic syndrome and obesity. Ann Surg. 2012;256:104–10.
doi: 10.1097/SLA.0b013e31825370c0
pubmed: 22609843
Sarkis R, Khazzaka A, Kassir R. Pilot study of a new model of bariatric surgery: laparoscopic intestinal bipartition-safety and efficacy against metabolic disorders. Obes Surg. 2018;28:3717–23.
doi: 10.1007/s11695-018-3483-6
pubmed: 30182334
Gagner M. Safety and efficacy of a side-to-side duodeno-ileal anastomosis for weight loss and type-2 diabetes: duodenal bipartition, a novel metabolic surgery procedure. Ann Surg Innov Res. 2015;9:6.
doi: 10.1186/s13022-015-0015-0
pubmed: 26473004
pmcid: 4607140
Yormaz S, Yılmaz H, Ece I, Sahin M. Laparoscopic ileal interposition with diverted sleeve gastrectomy versus laparoscopic transit bipartition with sleeve gastrectomy for better glycemic outcomes in T2DM patients. Obes Surg. 2018;28:77–86.
doi: 10.1007/s11695-017-2803-6
pubmed: 28681261
Santoro S, Mota FC, Aquino CG. Treating severe GERD and obesity with a sleeve gastrectomy with cardioplication and a transit bipartition. Obes Surg. 2019;29:1439–41.
doi: 10.1007/s11695-019-03752-4
pubmed: 30737760
Sengupta P. The laboratory rat: relating its age with human’s. Int J Prev Med. 2013;4:624–30.
pubmed: 23930179
pmcid: 3733029
Andreollo NA, dos Santos EF, Araújo MR, Lopes LR. Rat’s age versus human’s age: what is the relationship? Arq Bras Cir Dig. 2012;25(1):49–51.
doi: 10.1590/S0102-67202012000100011
pubmed: 22569979
Tessier R, Ribeiro-Parenti L, Bruneau O, Khodorova N, Cavin J-B, Bado A, et al. Effect of different bariatric surgeries on dietary protein bioavailability in rats. Am J Physiol Gastrointest Liver Physiol. 2019;317:G592–601.
doi: 10.1152/ajpgi.00142.2019
pubmed: 31460792
Liu P, Widjaja J, Dolo PR, Yao L, Hong J, Shao Y, et al. Comparing the anti-diabetic effect of sleeve gastrectomy with transit bipartition against sleeve gastrectomy and Roux-en-Y gastric bypass using a diabetic rodent model. Obes Surg. 2021;31:2203–10.
doi: 10.1007/s11695-021-05256-6
pubmed: 33507518
Wang M, Widjaja J, Dolo PR, Yao L, Hong J, Zhu X. The protective effect of transit bipartition and its modification against sleeve gastrectomy-related esophagitis in a rodent model. Obes Surg. 2022;32:1149–56.
doi: 10.1007/s11695-022-05907-2
pubmed: 35103916
Cavin J-B, Voitellier E, Cluzeaud F, Kapel N, Marmuse J-P, Chevallier J-M, et al. Malabsorption and intestinal adaptation after one anastomosis gastric bypass compared with Roux-en-Y gastric bypass in rats. Am J Physiol Gastrointest Liver Physiol. 2016;311:G492–500.
doi: 10.1152/ajpgi.00197.2016
pubmed: 27418681
Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014:CD003641. https://doi.org/10.1002/14651858.CD003641 .
Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13(1–190):215–357.
Guimarães M, Osório C, Silva D, Almeida RF, Reis A, Cardoso S, et al. How sustained is Roux-en-Y gastric bypass long-term efficacy?: Roux-en-Y gastric bypass efficacy. Obes Surg. 2021;31:3623–9.
doi: 10.1007/s11695-021-05458-y
pubmed: 34021884
pmcid: 8270797
Soong T-C, Lee M-H, Lee W-J, Almalki OM, Chen J-C, Wu C-C, et al. Long-term efficacy of bariatric surgery for the treatment of super-obesity: comparison of SG, RYGB, and OAGB. Obes Surg. 2021;31:3391–9.
doi: 10.1007/s11695-021-05464-0
pubmed: 33993423
Maciejewski ML, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS, Weidenbacher HJ, et al. Bariatric surgery and long-term durability of weight loss. JAMA Surg. 2016;151:1046–55.
doi: 10.1001/jamasurg.2016.2317
pubmed: 27579793
pmcid: 5112115
Calisir A, Ece I, Yilmaz H, Alptekin H, Acar F, Yormaz S, et al. The mid-term effects of transit bipartition with sleeve gastrectomy on glycemic control, weight loss, and nutritional status in patients with type 2 diabetes mellitus: a retrospective analysis of a 3-year follow-up. Obes Surg. 2021;31:4724–33.
doi: 10.1007/s11695-021-05536-1
pubmed: 34195935
Karaca FC. Effects of sleeve gastrectomy with transit bipartition on glycemic variables, lipid profile, liver enzymes, and nutritional status in type 2 diabetes mellitus patients. Obes Surg. 2020;30:1437–45.
doi: 10.1007/s11695-019-04326-0
pubmed: 31984455
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.
doi: 10.1056/NEJMoa1200111
pubmed: 22449317
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Capristo E, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397:293–304.
doi: 10.1016/S0140-6736(20)32649-0
pubmed: 33485454
Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376:641–51.
doi: 10.1056/NEJMoa1600869
pubmed: 28199805
pmcid: 5451258
Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353:249–54.
doi: 10.1056/NEJMoa043690
pubmed: 16034010
Smith EP, Polanco G, Yaqub A, Salehi M. Altered glucose metabolism after bariatric surgery: what’s GLP-1 got to do with it? Metabolism. 2018;83:159–66.
doi: 10.1016/j.metabol.2017.10.014
pubmed: 29113813
Egerod KL, Engelstoft MS, Grunddal KV, Nøhr MK, Secher A, Sakata I, et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology. 2012;153:5782–95.
doi: 10.1210/en.2012-1595
pubmed: 23064014
pmcid: 7958714
Thondam SK, Cuthbertson DJ, Wilding JPH. The influence of glucose-dependent insulinotropic polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Peptides. 2020;125:170208.
doi: 10.1016/j.peptides.2019.170208
pubmed: 31759125
Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, et al. Leptin and obesity: role and clinical implication. Front Endocrinol (Lausanne). 2021;12:585887.
doi: 10.3389/fendo.2021.585887
pubmed: 34084149
pmcid: 8167040
Gómez-Ambrosi J, Gallego-Escuredo JM, Catalán V, Rodríguez A, Domingo P, Moncada R, et al. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. Clin Nutr. 2017;36:861–8.
doi: 10.1016/j.clnu.2016.04.027
pubmed: 27188262
Alvarez-Sola G, Uriarte I, Latasa MU, Fernandez-Barrena MG, Urtasun R, Elizalde M, et al. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration. Gut. 2017;66:1818–28.
doi: 10.1136/gutjnl-2016-312975
pubmed: 28119353
Hosseinzadeh A, Roever L, Alizadeh S. Surgery-induced weight loss and changes in hormonally active fibroblast growth factors: a systematic review and meta-analysis. Obes Surg. 2020;30:4046–60.
doi: 10.1007/s11695-020-04807-7
pubmed: 32621056
Rebelos E, Moriconi D, Honka M-J, Anselmino M, Nannipieri M. Decreased weight loss following bariatric surgery in patients with type 2 diabetes. Obes Surg. 2022;33(1):179–87.
doi: 10.1007/s11695-022-06350-z
pubmed: 36322345
pmcid: 9834097
Campos GM, Khoraki J, Browning MG, Pessoa BM, Mazzini GS, Wolfe L. Changes in utilization of bariatric surgery in the United States from 1993 to 2016. Ann Surg. 2020;271:201–9.
doi: 10.1097/SLA.0000000000003554
pubmed: 31425292